Switching Between GLP-1 Medications: Dose Conversion Guide

Introduction

There are good reasons to switch GLP-1 medications mid-treatment. Side effects on one agent that don’t show up on another. Plateaued weight loss. Cost or supply changes. SURMOUNT-5 (Aronne et al. 2024 NEJM) showed tirzepatide produced 47% more weight loss than semaglutide head-to-head, which has pushed many patients to switch from one to the other.

There’s no FDA-approved switching protocol. Clinical practice has standardized roughly equivalent doses, with a brief washout period and dose titration on the new agent to manage side effects. This guide covers the conversion math, the timing, and what to expect during the transition.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

Why Do Patients Switch GLP-1 Medications?

Plateau is the most common reason. A patient who’s been on semaglutide for 12 months and hit a maintenance ceiling at 12% weight loss may switch to tirzepatide to push further, since tirzepatide’s combined GLP-1/GIP action typically produces more weight loss.

Quick Answer: SURMOUNT-5 (Aronne 2024 NEJM): tirzepatide 15 mg produced 47% greater weight loss than semaglutide 2.4 mg head-to-head

Side effects drive another large share of switches. Persistent nausea or GI distress on one medication sometimes resolves on the other. The mechanism difference matters: tirzepatide’s GIP component appears to mitigate some GI side effects in subgroup analyses.

Supply issues drove substantial switching during the 2022 to 2024 semaglutide shortage period. Patients moved to tirzepatide or compounded versions to maintain treatment.

Cost considerations drive switches in both directions, depending on insurance coverage and which medication has better access at any given time.

What’s the Dose Conversion Table for Semaglutide to Tirzepatide?

There’s no FDA-approved equivalence chart, but clinical practice has converged on roughly these mappings based on weight loss outcomes in STEP and SURMOUNT trials:

Semaglutide 0.25 mg ↔ Tirzepatide 2.5 mg (starting doses on both)

Semaglutide 0.5 mg ↔ Tirzepatide 5 mg

Semaglutide 1.0 mg ↔ Tirzepatide 7.5 mg

Semaglutide 1.7 mg ↔ Tirzepatide 10 mg

Semaglutide 2.4 mg ↔ Tirzepatide 12.5 to 15 mg

The conversion isn’t exact because the medications work through different mechanisms. Tirzepatide’s GIP activity adds metabolic effects beyond what semaglutide produces at “equivalent” doses.

Should I Switch up or Down When I Move to the New Medication?

Most clinicians err on the side of starting low. When switching from semaglutide 2.4 mg to tirzepatide, common practice is to start at 5 mg tirzepatide rather than 10 to 15 mg, then titrate over 4 to 8 weeks. This reduces side effect burden during the transition.

When switching from tirzepatide to semaglutide, start at 0.5 mg or 1.0 mg semaglutide rather than 2.4 mg. The mechanism switch (losing GIP) often produces a noticeable hunger return, so faster titration is sometimes appropriate, but starting cautiously is safer.

The exception: if you’re switching purely because of supply (not tolerability or efficacy issues) and you tolerated the previous agent well, you can often start at an equivalent dose without significant problems.

How Long Should the Washout Be Between Medications?

For weekly injectables, the standard washout is one missed dose, meaning you skip one weekly injection of the old medication and start the new one a week later. This corresponds to roughly 50% clearance for semaglutide (7-day half-life) and 75% clearance for tirzepatide (5-day half-life) at the time of the first new dose.

Some clinicians prefer a longer washout (2 to 3 weeks) for patients on maximum doses to clear more of the previous medication before adding the new one. This reduces the small risk of overlapping GLP-1 effects causing severe nausea or hypoglycemia.

For diabetes patients on multiple glucose-lowering medications, longer washouts and tighter glucose monitoring during the transition are warranted.

What Head-to-head Data Exists for These Medications?

SURMOUNT-5 (Aronne 2024 NEJM) is the most important comparison. The trial randomized 751 adults with obesity (without diabetes) to tirzepatide max-tolerated dose or semaglutide 2.4 mg, treated for 72 weeks.

Results: tirzepatide produced 20.2% mean weight loss versus semaglutide’s 13.7%. Tirzepatide patients were more likely to hit 15%, 20%, and 25% weight loss thresholds. Side effect profiles were similar; tirzepatide had marginally more GI side effects but the difference was small.

The implication is that for patients who haven’t responded well to semaglutide and want more weight loss, switching to tirzepatide is supported by direct head-to-head data.

What Happens to Weight Loss During the Switch?

Most patients see a brief plateau or slight regain (1 to 3 lb) during the washout and titration phase, then resume weight loss as the new medication reaches therapeutic levels. The total transition takes 4 to 12 weeks depending on starting dose and titration speed.

Expect 4 to 6 weeks before you feel the new medication is “working” at the dose you’re titrating toward. Tirzepatide’s appetite suppression at 5 mg often takes 3 to 4 weeks to reach full effect.

Do Side Effects Reset When Switching?

Mostly yes. The GI tolerance you built up on the old medication doesn’t fully transfer to the new one. Patients who were on semaglutide 2.4 mg with no nausea sometimes get nausea on tirzepatide 5 mg, even though that’s a “lower” effective dose.

This is why starting low and titrating slowly matters. The receptor adaptation that suppresses side effects is medication-specific to some degree.

What helps during the transition: small meals, low-fat foods, hydration, and not pushing through severe nausea. If a dose causes problems, stay at that dose for an extra 4 weeks before trying to escalate.

Can You Switch From Oral Semaglutide (Rybelsus®) to Injectable?

Yes, and it’s a common move. Rybelsus 14 mg oral has roughly the systemic exposure of semaglutide 0.5 mg injectable, so the conversion is approximate:

Rybelsus 7 mg → semaglutide injectable 0.25 mg

Rybelsus 14 mg → semaglutide injectable 0.5 mg

Higher injectable doses (1.0, 1.7, 2.4 mg) don’t have oral equivalents because oral semaglutide tops out at 14 mg.

Patients who want weight loss beyond what Rybelsus delivers typically switch to injectable semaglutide and titrate up to 2.4 mg, or switch directly to tirzepatide.

Key Takeaway: Start the new medication at a low dose and titrate; previous tolerance doesn’t fully carry over

What About Switching From Compounded to Brand-name?

The dose-for-dose conversion is straightforward when concentrations match. Compounded semaglutide 0.5 mg should be equivalent to brand semaglutide 0.5 mg, assuming the compounded version meets quality standards.

Where things get more complex is with compounded blends (semaglutide + B12, semaglutide + cyanocobalamin, etc.). The active GLP-1 dose still transfers, but additional components may produce different subjective experiences.

Patients who switch from compounded to brand sometimes report different injection site reactions or slightly different efficacy. These usually resolve within 4 to 8 weeks of consistent dosing on the new formulation.

Are There Any Medications You Shouldn’t Switch to GLP-1 From?

Most GLP-1 to GLP-1 switches are routine. The transitions that require more careful planning:

From a long-acting GLP-1 with renal impairment, where dose adjustments may differ between agents.

From a GLP-1 to a different drug class (Contrave, phentermine, Saxenda® the older daily GLP-1). The mechanism shifts entirely.

From insulin + GLP-1 combinations in diabetes, where insulin doses need re-evaluation during the switch.

For complicated medication regimens, consultation with the prescribing physician before switching is non-negotiable.

What If You’re Switching for Cost Reasons?

Cost-driven switches happen frequently as insurance coverage changes, manufacturer pricing shifts, and compounded options come and go. The decision framework:

Same molecule, different brand or formulation: usually straightforward switch with minimal adjustment needed (e.g., brand semaglutide to compounded semaglutide at the same concentration).

Different molecule (semaglutide to tirzepatide or vice versa): requires the full switching protocol described above.

Brand to compounded: choose a quality-verified compounding pharmacy. Concentration may differ from brand pens, so dose-equivalency calculations matter.

Compounded to brand: typically a step up in quality oversight but down in dose flexibility. Match dose to nearest available brand strength.

For all cost-driven switches, the medical content of the switch (washout, titration, monitoring) is the same as a clinically-driven switch. Don’t skip steps because the motivation is financial.

What About Switching Between Different Compounded Versions?

Some patients move between compounded providers for cost, quality, or convenience reasons. Considerations:

Concentration matters. Different compounders use different concentrations (some at 2.5 mg/mL, others at 5 mg/mL, etc.). Equivalent doses may require different injection volumes between providers.

Additives may differ. Some compounded semaglutide includes B12 or cyanocobalamin; others are semaglutide-only. Switching can produce different subjective experiences.

Quality consistency varies. If your current provider produces a stable product, switching introduces uncertainty. Reasons to switch should outweigh this risk.

A 2 to 4 week stabilization period at the new provider’s product helps assess whether the switch is working.

How Should You Monitor During a Switch?

Weight weekly for the first 8 to 12 weeks. Side effect tracking (nausea, GI changes, fatigue) to inform titration pace. Blood sugar monitoring if you have diabetes. Blood pressure if you’ve had cardiovascular concerns.

Plan a follow-up visit at 8 to 12 weeks to assess whether the switch is achieving its goals. If weight loss hasn’t resumed by week 12 and you’ve titrated to a reasonable dose, the switch may not be doing what you hoped.

TrimRx supports switching protocols through telehealth check-ins as part of the personalized treatment plan that comes with the initial assessment quiz.

What If You’ve Switched and the New Medication Isn’t Tolerable?

Sometimes a switch doesn’t work as planned. The patient experiences worse side effects on the new medication, or efficacy is lower than expected. Options:

Lower dose. If side effects are the issue, dropping back to a lower dose on the new medication and titrating more slowly often resolves the problem.

Pause and retry. A 4 to 8 week pause from the new medication before retrying the same titration sometimes works when the initial attempt failed.

Switch back. If the previous medication worked well and the new one isn’t fitting, switching back is reasonable. Restart at a moderate dose of the original medication and re-titrate.

Try a third option. If neither semaglutide nor tirzepatide work well, other obesity medications (Saxenda, Contrave, phentermine combinations) may be alternatives, though typically with smaller effect sizes.

The decision to abandon a switch should come after at least 8 to 12 weeks at a therapeutic dose of the new medication, not after 2 to 3 weeks of initial titration discomfort.

Bottom line: About 15-25% of patients switch GLP-1 agents at some point during treatment

FAQ

How Long Does the Whole Switch Take?

From last dose of the old medication to therapeutic dose of the new one, plan for 6 to 12 weeks. Faster if you’re going to an equivalent dose; slower if you’re starting low and titrating.

Will I Gain Weight During the Switch?

Most patients see a small bump (1 to 3 lb) during the washout and titration phase. Larger gains suggest the new dose isn’t yet therapeutic. Weight loss usually resumes by week 4 to 6 of the new medication.

Can I Switch Back If the New Medication Doesn’t Work for Me?

Yes. Reverse the protocol, washout, restart the original. There’s no penalty to multiple switches beyond the time spent in transition.

Is It Safe to Overlap Medications During a Transition?

Generally no. Concurrent GLP-1 dosing increases risk of severe nausea, hypoglycemia, and other side effects. A clean washout is the standard approach.

Will My Insurance Cover the Switch?

Depends on the plan. Most insurers cover one preferred GLP-1 medication. Switching often requires a new prior authorization with documentation of why the switch is medically necessary (intolerance, plateau, etc.).

Do I Need a New Prescription?

Yes. Each medication is a separate prescription. Your provider will write the new prescription and discontinue the old one.

How Do I Know If the Switch Worked?

Look at three things at week 12: weight trend, side effect profile, and subjective experience (hunger, energy, food noise). If two or three are better than before, the switch worked. If they’re worse, consider switching back.

Can I Switch Dose Levels Without Switching Medications?

Yes, that’s a dose adjustment rather than a switch. Going from semaglutide 1.0 to 2.4 mg, or tirzepatide 5 to 10 mg, doesn’t require washout or special protocol beyond standard titration.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.